United Therapeutics Sells Priority Review Voucher to AbbVie

US biotechnology company United Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Boucher (PPRV) to a subsidiary of biopharmaceutical firm AbbVie for $350 million.

United Therapeutics received the PPRV when its unituxin treatment for neuroblastoma was approved by the US Food and Drug Administration (FDA).

“We are very pleased to monetize our PPRV, and hope that this transaction will encourage others to join us in focusing development efforts on rare pediatric diseases,” said Roger Jeffs, president and co-CEO of United Therapeutics.

The PPRV program encourages the development of new drugs and biologics for preventing and treating rare pediatric diseases. A PPRV entitles the holder to priority review of a single new drug application or biologics license application, which reduces the target review time and could lead to an expedited approval.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.